ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- The role of viruses in cancer development versus cancer therapy: An oncological perspective.Cancer medicine · 2023Review
- Newcastle Disease Virus Manipulates Mitochondrial MTHFD2-Mediated Nucleotide Metabolism for Virus Replication.Journal of virology · 2023Article
- Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.Oxidative medicine and cellular longevity · 2022Review
- Oncolytic virus therapy in cancer: A current review.World journal of virology · 2021Review
- The Oncolytic Virus in Cancer Diagnosis and Treatment.Frontiers in oncology · 2020Review
- Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.Molecular therapy oncolytics · 2019Review
- In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics.PLoS computational biology · 2019Article
- Oncolytic viruses: adenoviruses.Virus genes · 2017Review
- OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.Molecular therapy oncolytics · 2017Article
- Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Biomedicines · 2016Review
- Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq.Oncotarget · 2015Article
- Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice.BMC cancer · 2015Article
- Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications.Oncolytic virotherapy · 2015Review
- CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.BMC cancer · 2014Article
- Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.Cancer gene therapy · 2014Article
- Combined cytolytic effects of a vaccinia virus encoding a single chain trimer of MHC-I with a Tax-epitope and Tax-specific CTLs on HTLV-I-infected cells in a rat model.BioMed research international · 2014Article
- Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.Human gene therapy · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Oncolytic viruses consist of a diverse range of DNA and RNA viruses traditionally thought to mediate their effects by exploiting aberrations in tumor pathways, allowing preferential viral replication in, and killing of, tumor cells. Clinical development has progressed to late-phase trials, potentially heralding their introduction into clinical practice. However, despite this promise, the activity of oncolytic viruses has yet to achieve the potential suggested in preclinical models. To address this disparity, we need to recognize the complex interaction among oncolytic viruses, tumor, chemotherapy, and host immune system, and appreciate that direct oncolysis may not be the only factor to play an important role in oncolytic virus-mediated antitumor efficacy. Although key in inactivating viruses, the host immune system can also act as an ally against tumors, interacting with oncolytic viruses under the right conditions to generate useful and long-lasting antitumor immunity. Preclinical data also suggest that oncolytic viruses show synergy with standard therapies, which may offer improved clinical response rates. Here, we explore clinical and preclinical data on clinically relevant oncolytic viruses, highlighting areas of progress, uncertainty, and translational opportunity, with respect to immune recruitment and therapeutic synergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.